Clinical Study of ADS Cream (Medicated Atskin®Cream) in Atopic Dermatitis

• Published in: Skin research Vol. 38; no. 1; pp. 74 - 96
• Main Authors: SUGIYAMA, Asami, OHSAWA, Junko, KITAMURA, Kazuko, KOMATSU, Taira, IKEZAWA, Zenroh
• Format: Journal Article
• Language: Japanese
• Published: Meeting of Osaka Dermatological Association 1996; 日本皮膚科学会大阪地方会
• Subjects: atopic dermatitis; clinical study; dermato-physiological parameter; medicated Atskin®cream; skin care; アトピー性皮膚炎; スキンケア; 皮膚生理パラメーター; 臨床試験; 薬用アトスキンクリーム
• ISSN: 0018-1390; 1884-541X
• DOI: 10.11340/skinresearch1959.38.74

A clinical study of ADS cream (medicated Atskin® cream) which is compounded of squalane and jojoba oil as the main bases, a derivative of glycyrrhetic acid and allantoin as the active ingredients, and sodium hyaluronate as the humectant was conducted in 99 patients with mild to moderate atopic dermatitis (AD) to evaluate utility. The rate of improvement which was determined from general improvement rating was 35.4%(including evaluations classified as “moderately and remarkably improved”) and 78.8%(including evaluations classified as “sligtly, moderately, and remarkably improved”). The rate of improvement by symptom was especially high, 78.4% and 75.0%, for dry skin and scale, respectively, and the rates for an itching sensation and scratch marks were also relatively high, 56.1% and 53.1% respectively. Adverse reactions to this cream were reported in 3 patients (3.0%), the symptoms consisting of a tingling sensation in 1 patient, itching, erythema, and papule in 1 patient, and papule in 1 patient. The rate of utility which was determined in consideration of the general improvement rating and adverse reactions was high, 42.4%(including eveluations classified as “moderately and vety useful”) and 75.8%(including evaluations classified as “slightly, moderately, and very useful”). To evaluate the effect of ADS cream on the physiological condition of skin in a non-invasive way, the moisture content of the stratum corneum (corneous conductance), transepidermal water loss (TWL), and skin surface morphology (VC1: a parameter showing the radial heterogeneity of askin fissure) were determined. Apart from the above-mentioned study, 23 patients with mild to moderate AD were given ADS cream for about 4 weeks to evaluate the dermato-physiological parameters and its clinical effect. The rate of improvement which was determined fom the general improvement rating was 43.5%(including evaluations classified as “moderately and remarkably improved”) and 73.9%(including evaluations classified as “slightly, moderately, and remarkably improved”). The rate of improvement by symptom was more than 70.0% for dry skin, scale, and scratch marks, more than 60% for erythema and pauple, and more than 50% for an itching sensation. These findings roughly coincide with those obtained in the previous study (in 99 subjects). The results of dermato-physiological parameter measurement indicate an improvement in the physiological condition of the stratum corneum, as shown by a significant increase in the moisture content of the stratum corneum (p<0.05) and a significant decrease in fissural heterogeneity (p<0.05). In addition, the mean value of TWL tended to be slightly lower after use than before use, though there was no significant difference, i.e., improvement in skin surface barrier function was suggested. In conclusion, the results presented suggest that ADS cream may be useful as skin care cream intended for self-medication in AD patients because clinical symptoms, the moisture content of the stratum corneum, and skin sureface morphology were improved in such patients by the use of it.